U.S. Markets close in 1 hr 10 mins
  • Barrons.com2 hours ago

    Gilead: The Worst is Over?

    The sleeping giant has awakened. Which makes it a perfect time for an analyst to start Gilead Sciences' (GILD) stock with a buy rating. It centers on Gilead's valuation, a thesis that "is not new, but is also not necessarily wrong." They explain: While we fully expect Gilead to ultimately (and yes, eventually) pursue and execute on a business development strategy that should prove transformative (and hence render our outlook on the existing business less relevant) we believe concerns around the stock being a "value trap" for investors will soon come to pass.

  • TheStreet.com3 hours ago

    Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

    The stock has been on fire.

  • Benzinga5 hours ago

    Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

    Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...